webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

DM4-SPDB

  CAS No.: 1626359-62-3   Cat No.: BADC-00012   Purity: ≥98% 4.5  

DM4 with a reactive linker SPDB, which can react with antibody to make antibody drug conjugate. DM4 can bind to tubulin at or near the vinblastine-binding site.

DM4-SPDB

Structure of 1626359-62-3

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C46H63ClN4O14S2
Molecular Weight
995.59
Shipping
Room temperature, or blue ice upon request.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
1 mg $519 In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-Chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10(26),11,13,16,18-pentaen-6-yl (2 S)-2-{[4-({4-[(2,5-dioxo-1-pyrrolidinyl)oxy]-4-oxobutyl}disulfanyl)-4-methylpentanoyl](methyl)amino}propanoate (non-preferred name); DM4 SPDB
IUPAC Name
(2,5-dioxopyrrolidin-1-yl) 4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]butanoate
Canonical SMILES
CC1=CC=C[C@H]([C@]2(C[C@@H]([C@@H](C)[C@H]3[C@](C)([C@H](CC(=O)N(C)C4=C(C(=CC(=C4)C1)OC)Cl)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCCC(=O)ON5C(=O)CCC5=O)O3)OC(=N2)O)O)OC C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/Cc3cc(c(c(c3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCCC(=O)ON5C(=O)CCC5=O)C)\C)OC)(NC(=O)O2)O
InChI
InChI=1S/C46H63ClN4O14S2/c1-26-13-11-14-33(61-10)46(59)25-32(62-43(58)48-46)27(2)41-45(6,64-41)34(24-38(55)50(8)30-22-29(21-26)23-31(60-9)40(30)47)63-42(57)28(3)49(7)35(52)18-19-44(4,5)67-66-20-12-15-39(56)65-51-36(53)16-17-37(51)54/h11,13-14,22-23,27-28,32-34,41,59H,12,15-21,24-25H2,1-10H3,(H,48,58)/b14-11+,26-13+/t27-,28+,32+,33-,34+,41+,45+,46+/m1/s1
InChIKey
LAVNQRWLLQGEIB-BAQPUJNESA-N
Appearance
Soild powder
Shipping
Room temperature, or blue ice upon request.

DM4-SPDB is a cutting-edge chemical compound used in the field of targeted cancer therapies, particularly in the development of Antibody-Drug Conjugates (ADCs). ADCs represent a revolutionary class of cancer treatments that combine the targeting ability of monoclonal antibodies with the potent cell-killing ability of cytotoxic drugs. DM4, or N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)-maytansine, serves as the cytotoxic agent, while SPDB, N-Succinimidyl-4-(2-pyridyldithio)-butyrate, acts as the reactive linker. This linker exploits the functional groups available on antibodies to conjugate the powerful DM4 payload, ensuring the selective delivery of the drug to cancer cells that express specific antigens on their surface, thereby minimizing the impact on healthy cells.

The unique mechanism of DM4 enhances its attraction as a component of ADCs. Its primary action is to bind to tubulin, a key protein involved in cell division, at a location close to or at the vinblastine-binding site. This binding disrupts microtubule function, essential for cancer cell mitosis and proliferation, leading to cell cycle arrest and apoptosis. By targeting tubulin, DM4 can effectively halt the rapid division of cancer cells, a hallmark of malignancy. The ability to bind at or near the vinblastine site not only confirms its potency but also suggests potential synergistic effects when used in combination with other chemotherapy drugs.

The incorporation of SPDB as a linker is a strategic choice due to its bifunctional nature, which allows for efficient conjugation. SPDB facilitates a stable yet cleavable connection between the antibody and DM4, which is crucial for the drug’s targeted action upon reaching the tumor microenvironment. Ideally, the linker remains stable in the bloodstream to prevent premature release of the cytotoxic agent, thereby reducing systemic toxicity. Upon entering the tumor cell, the intracellular milieu, which often differs from the extracellular environment, can trigger the release of DM4. This specificity enhances the therapeutic window of ADCs, improving efficacy while minimizing adverse effects.

In drug discovery and development, DM4-SPDB plays a pivotal role in designing ADCs that can address unmet medical needs in oncology. Its ability to differentiate between cancerous and non-cancerous cells allows researchers to create safer, more effective cancer therapies. This innovation not only enhances treatment outcomes but also holds the potential to address various cancer types, particularly those resistant to conventional therapies. Current research aims at improving the selectivity of antibodies used, optimizing the linker chemistry, and overcoming resistance mechanisms. These efforts are motivated by the significant promise ADCs hold in redefining cancer treatment paradigms.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: PC SPDP-NHS carbonate ester | Disitamab vedotin | Fmoc-Val-Ala-PAB-PNP | 1-(4-((3-(dimethylcarbamoyl)pyridin-4-yl)disulfanyl)pentanoyloxy)-2,5-dioxopyrrolidine-3-sulfonic acid | MC-Alkyl-Hydrazine Modified MMAF | Cys-MC-MMAF | Indatuximab ravtansine | PEG4-aminooxy-MMAF | sulfo-SPDB-DM4 | Sulfo-PDBA-DM4 | DM4-SPDB
Send Inquiry
Verification code
Inquiry Basket